Enrollment Complete in SAFFRON Global Phase III

Updates from R&D Event

HUTCHMED Presents Data at AACR NCI EORTC

Vesting of awards under Long Term Incentive Plan

Appointment of Independent Non-executive Director

Data to be Presented at the 2025 ESMO Congress

HUTCHMED Highlights Data to be Presented at ESMO

Total Voting Rights

HUTCHMED to Present R&D Updates on October 31 2025

HUTCHMED Highlights Data to be Presented at CSCO

Directorate Change

HUTCHMED Completes Enrollment of Phase III Trial

2025 Interim Results

HUTCHMED to Announce 2025 Half-Year Results

Update on Joint Corporate Brokers in London

China Approval based on Phase III SACHI Trial

Total Voting Rights

Blocklisting Six Monthly Return

Grant of Share Options and Awards under LTIP

HUTCHMED and Innovent Announce NDA Acceptance

HUTCHMED Highlights SACHI Phase III Data at ASCO

Total Voting Rights

HUTCHMED Highlights Data to be Presented at ASCO

AGM held on May 13, 2025 – Poll Results

HUTCHMED - Data to be Presented at AACR 2025

HUTCHMED Completes Enrollment of Phase II Study

2024 Annual Report and Notice of AGM

Extraordinary General Meeting – Poll Results

NMPA Conditional Approval for TAZVERIK®

Retirement of Independent Non-executive Directors

HUTCHMED Highlights Savolitinib SAVANNAH Phase II

2024 Final Results and Business Updates

Phase II/III Study of Fruquintinib and Sintilimab

Adoption of the 2025 Long Term Incentive Plan

Vesting of awards under Long Term Incentive Plan

Notice of Extraordinary General Meeting

Completed Enrollment of Phase II Study

Directorate Change

Overseas Regulatory Announcement

Overseas Regulatory Announcement

Notice of Results

Overseas Regulatory Announcement

Full Approval for ORPATHYS in China

Overseas Regulatory Announcement

US$608m Divestment of Non-Core Joint Venture

Appointment of Joint Corporate Broker

Blocklisting Six Monthly Return

HUTCHMED to Receive Milestone Payment from Takeda

HUTCHMED and Innovent Announce ELUNATE Approval

Total Voting Rights

Appointment of Independent Non-executive Director

Total Voting Rights

Vesting of awards under the LTIP

SAVANNAH: clinically meaningful response rate

Japan Approval for FRUZAQLA

Total Voting Rights

Update on Fruquintinib for Gastric Cancer in China

LTIP and Share Option Scheme

2024 Interim Results and Business Updates

Blocklisting Six Monthly Return

Total Voting Rights

HUTCHMED to Announce 2024 HY Financial Results

European Commission Approval for FRUZAQLA

Total Voting Rights

Retirement of Chairman and new Chairman appointed

Result of AGM

Directorate Change

Positive CHMP Opinion for Fruquintinib

Vesting of Awards Under the LTIP

2023 Annual Report and Notice of AGM

LTIP and Share Option Scheme

Vesting of awards under the LTIP

2023 Full Year Results and Business Updates

HUTCHMED to Announce 2023 Final Results

Total Voting Rights

Blocklisting Six Monthly Return

Overseas Regulatory Announcement

Overseas Regulatory Announcement

Total Voting Rights

U.S. FDA Approval of FRUZAQLAâ„¢ (fruquintinib)

Vesting of awards under the LTIP

Total Voting Rights

Director’s Share Dealing

Total Voting Rights

Sovleplenib Phase 3 Study Meets Primary Endpoint

Exercise of Share Options by a Director

Interim Results and Business Updates

Changes to Board and Technical Committee

Blocklisting Six Monthly Return

HUTCHMED to Announce 2023 Half-Year Results

Phase III FRESCO-2 Results in The Lancet

MAA of Fruquintinib Validated by the EMA

LTIP and Share Option Scheme

Total Voting Rights

Fruquintinib NDA Granted Priority Review by FDA

Annual General Meeting Poll Results

Board of Directors and Board Committee Membership

Appointment of Independent NED